
Focus Areas
Three Markets
Anti-Aging Cosmeceuticals

Pulmonary Disorders

The NanoNOx Inhaler Drug Delivery Platform
The NanoNOx Inhaler delivers NanoNOx as an alternative to inhaled nitric oxide gas delivery. NanoNOx offers drug Delivery & Palliative Asthma/COPD Relief, without steroids.
NanoNOx Unique Patentes Inhaler Technology.

NanoNOx can deliver encapsulated NO as an alternative to inhaled NO gas delivery platform – Stand alone or combined with drug.
Features:
​
No heat, No Battery.
​
Liquid is vaporized into nano scale droplets for inhalation.
​
Liquid contains NanoNOx alone or NanoNOx with other molecule.
NanoNOx delivers effectively to the bronchial tubes in the upper lobes of the lungs because of much smaller nanoparticles unlike inhalers/nebulizers.
The NanoNOx Solution can deliver NO nanoparticles over 4-12 hours, tunable by application and molecule.
The Markets: The COPD & Asthma $39 B market and $1.243 B drug delivery market 1+2
The NanoNOx Inhaler can treat the following Disorders:
Pulmonary Hypertension
Acute Respiratory Distress Syndrom (ARDS)
Pediatric Bronchitis
Chronic obstructive Pulmonary Distress (COPD)
Systic Fibrosis
NanoNOx Competitors:
Inhalation (Gas, Inhalers, Nebulizers) & NO Macroparticles
TM
NanoNOx’s Advantages: Timed Release, Dosage & Precise Delivery
Advantages of NanoNOx Inhaler
vs
NO Gas Tanks today
1.NO Tank Gas has 30-60 sec half life for
in situ use
vs
NanoNOx timed release, up to 12 hours
​
​
2.NanoNOx handheld inhaler provides portable flexibility not easily done with tanks


Advantages of NanoNOx Inhaler
vs
Standard Inhalers & Nebulizers
1.Only device to use NO’s vasodilator and anti-inflammatory characteristics to enhance drug absorption
​
​
2.Competitors deliver larger macroparticles that do not reach the upper lobes well because of sizes generally are 400-600 nm


Advantages of NanoNOx Nanoparticle
vs
L Arginine, L Citrulline, SNP, SNAP and other NO Macroparticles
1.Other NO macroparticle delivery systems lack ability to cross cell membrane with pure NO
​
2.Other NOs lack stability
​
3.Other NOs may lack NO dosage precision and the ability to deliver sufficient NO dosage for efficacy
​
4.Other NO macroparticles require cascade of reactions before crossing cell membrane with NO
​
5.NO inducing drugs cause systemic risks



